Neurizon strengthens leadership team

Australian clinical-stage biotech Neurizon Therapeutics (ASX: NUZ & NUZOA), which is advancing innovative treatments for neurodegenerative diseases, has significantly strengthened its executive management team with three key appointments.

These include Kathryn Williams as chief regulatory officer (CRO), Dr Jeffrey Brown as chief scientific advisor (CSA), and Dr Chris Freitag as chief medical advisor (CMA).

Neurizon says these appointments provide the company with broader expertise in regulatory affairs, clinical development and commercialisation, and will assist in accelerating Neurizon’s stated strategy to advance its lead drug candidate, NUZ-001’s clinical development pathway, secure regulatory approvals, expand the pipeline in neurodegenerative diseases and optimize future market access. The combined expertise of Ms Williams, Dr Brown, and Dr Freitag will assist in the company’s near-term focus to lift the clinical hold for NUZ-001’s investigational new drug (IND) application to facilitate entry into the HEALEY ALS Platform Trial in H2 CY2025.